SNDX-5613 (Figure 5) is an analog of VTP-50469, which demonstrated significant activity in mouse models of NPM1-mutated AML, with some animals remaining in CR one year after treatment cessation [114,116]. Here, NPM1 is linked to acute myeloid leukemia.